Moleculent Raises $20M Series A for Functional Profiling
Moleculent, a Stockholm-based developer of platforms that detect high-plex cell-cell interactions in FFPE tissue, has raised $20M in Series A funding led by Rubicon Healthcare Partners. The round included participation from ARCH Venture Partners and Eir Ventures. The platform maps functional receptor-ligand pairs directly in native tissue to reveal how cells communicate in cancer and immuno-oncology. Funds will scale the Techstart Early Access Program, accelerate US commercial operations, and drive instrument commercialization.
Spatial Tools Secure Heavy Backing
The raise aligns with surging interest in spatial biology tools. Swedish peer Pixelgen Technologies raised $22M, while Vizgen has secured over $300M. Akoya Biosciences drew more than $200M before its acquisition. Moleculent differentiates by detecting active interactions via proximity ligation assays, not just protein expression or transcriptomics.
Expression Data Misses Interactions
Current spatial platforms profile gene or protein expression but cannot confirm functional cell-cell signaling. This gap limits insights into tumor microenvironments, where interactions drive resistance to immunotherapies like checkpoint inhibitors. Researchers need direct evidence of receptor-ligand binding to identify novel drug targets and predict responses.
Proximity Ligation Maps Real Signaling
Moleculent's proprietary multiplexed proximity ligation assay (PLA) visualizes active cell-cell communication at high plex in standard FFPE samples. Unlike transcriptomics tools from Vizgen or phenotyping from Akoya, it measures actual ligand-receptor pairs in situ. The Techstart program offers pilot projects processing two FFPE slides with expert analysis in open formats.
As Olle Ericsson, CEO, noted:
"The market is telling us it’s ready… This new funding allows us to move more aggressively…"
Funding Signals Commercial Push
Rubicon Healthcare Partners led the round, with Ole Dahlberg—former executive at Thermo Fisher and Qiagen—joining the board. ARCH Venture Partners, which backed Moleculent's prior raise, returned for this expansion-focused investment. The syndicate reflects conviction in functional proteomics scaling to match demand from pharma and academia in immuno-oncology.
Spatial Market Scales to Billions
The spatial biology market stands at $970M in 2025, projected to reach $2.37B by 2030 at 19% CAGR. Trends toward multi-omics integration and high-plex analysis fuel growth, especially in oncology. Competitors like 10x Genomics launched scalable platforms at AACR 2026, highlighting tissue-based tools' momentum.
Board Addition Boosts Expertise
Ole Dahlberg brings deep diagnostics commercialization experience from leading sales at Thermo Fisher and Qiagen. His addition validates Moleculent's path from early access to global instrument rollout. CEO Olle Ericsson leads a team advancing from Sweden to US markets.
US Expansion Accelerates Now
Proceeds target Techstart program growth for biopharma and academic pilots, alongside US hiring and automated instrument launch. Moleculent eyes broader immuno-oncology applications, building on conference presence at AACR and SITC. Partnerships like VCU Massey Cancer Center signal early traction.